Efflux pump like P-glycoprotein (P-gp) is known to be a major barrier to drug delivery. Functional P-glycoprotein has been recently identified in cornea and corneal cell lines. Thus, it is probable that P-glycoprotein may restrict in vivo ocular drug absorption, resulting in low ocular bioavailability. Experiments were designed using New Zealand albino (New Zealand White) rabbits to assess inhibitors of P-gp efflux to increase drug absorption. Anesthetized rabbits were given constant topical infusions of [
kinetic studies were conducted using a topical single-dose infusion method. Maximum inhibition of P-gp mediated efflux was observed with 500 M testosterone. Area under the curve (AUC) 0-ϱ of erythromycin with 500 M testosterone was almost 4 times higher than AUC 0-ϱ without any inhibitor. Rate of elimination (k 10 ) for erythromycin and those with inhibitors was found to be similar (141 Ϯ 23 min), suggesting that elimination pathways were not altered. All the inhibitors were found to be nontoxic. Verapamil also inhibited the efflux pump with moderate change in AUC 0-ϱ and C max compared with control. Thus, P-gp is found to be active in vivo, and it restricts topical erythromycin absorption across the cornea, which can be inhibited by known P-gp inhibitors. Therefore, ocular bioavailability of P-gp substrates can be significantly enhanced by proper selection of P-gp inhibitors.
Multidrug resistance to absorption of drugs is mainly due to three proteins, P-glycoprotein (P-gp), lung resistance-related protein, and multidrug resistance associated protein-1 (Cole et al., 1992; Scheper et al., 1993) . A variety of structurally and pharmacologically unrelated drugs and compounds are substrates for P-gp. These include anticancer drugs such as doxorubicin and daunorubicin (Shtil et al., 2000) , steroids such hydrocortisone and dexamethasone (Ueda et al., 1992) , human immunodeficiency virus protease inhibitors, such as ritonavir (Perloff et al., 2001 ) and saquinavir (Huisman et al., 2003) , and cardiac drugs such as digoxin and quinidine (Duvvuri et al., 2003) .
Such efflux pumps have been identified in the eye. In the eye, P-gp is expressed in the retinal capillary endothelial cells (Holash and Stewart, 1993) , retinal pigmented epithelial cells (Schlingemann et al., 1998) , ciliary nonpigmented epithelium (Wu et al., 1996) , conjunctival epithelial cells (Saha et al., 1998) , and iris and ciliary muscle cells (Holash and Stewart, 1993) . More recently, P-gp has been identified in the human and rabbit cornea for the first time in our laboratory (Dey et al., 2003) . Functional expression of P-gp has been demonstrated by studying rhodamine-123 efflux in primary rabbit corneal cultures and cell lines.
Topical administration is the preferred mode to treat diseases that affect the anterior chamber of the eye. A majority of topically applied drugs, including steroids (Kupferman and Leibowitz, 1974) , ␤-blockers (Schoenwald and Huang, 1983) , antibiotics (Barza et al., 1983) , and nonsteroidal anti-inflammatory agents (Agata et al., 1984) enter the eye through the cornea. Unfortunately, the disposition of drugs administered in this manner is not well understood, although it is generally agreed that bioavailability of topically applied drugs is extremely limited (Ͻ5%). Low ocular bioavailability so far has been attributed primarily to the inability of drug molecules to cross the lipoidal membrane and not attributed to any efflux proteins that might efflux molecules out of corneal epithelium into the precorneal fluid.
Although functional P-gp in cornea and corneal cell lines has been discovered, it has not yet been established that this efflux pump can function in vivo to modulate drug concentration and activity in the eye. Several pharmacokinetic models of varying complexity have been proposed to predict absorption and disposition of drugs applied topically to the eye (Lee and Robinson, 1979; Makoid and Robinson, 1979; Miller et al., 1981) . A classical pharmacokinetic approach predicts aqueous humor levels reasonably well; however, transcorneal absorption rate constant is very difficult to determine due to the complexity of the model. Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye has been described using a four-compartment classical model represented by a four exponential equation yielding eight equation parameters (Makoid and Robinson, 1979) . Although the experimental data fit the equation well, the calculated parameters could not be assigned to absorption, distribution, or elimination very accurately. Another pharmacokinetic model has been applied to pilocarpine pharmacokinetics that uses a physiologically based model (Lee and Robinson, 1979; Miller et al., 1981) . However, both modeling approaches are complex with regard to numerical analyses.
To simplify the approach and correctly estimate ocular absorption and absorption rate constant, a "topical infusion" model has been described previously (Eller et al., 1985) . In this model, a constant concentration of the drug is maintained on the cornea so that the effect of tear dynamics is minimized and simpler equations can be applied independent of modeling. During constant input, absorption, distribution, and elimination can be determined independent of the number of the peripheral compartments that are operative. Constant concentration was maintained through the use of a plastic cylindrical well containing the drug solution.
We conceptualized the use of a combination of the topical well infusion model and aqueous humor microdialysis sampling for precise prediction of ocular absorption. This method will also reduce interindividual variability and minimize the number of animals required. In this report, we have discussed the use of this novel technique to determine the ocular pharmacokinetics of erythromycin (a P-gp substrate). Molecular identification and functional characterization of P-gp in human and rabbit cornea has already been reported from our laboratory (Dey et al., 2003) . This study discusses the functional nature of P-gp in an in vivo rabbit model and delineates the role of P-gp in lowering ocular bioavailability of topically applied drugs. In addition, a partial protein sequence has been reported for the first time, which would help in further cloning and characterization of rabbit P-gp.
Materials and Methods
Materials. Cyclosporin A (CsA), quinidine, verapamil, and testosterone were purchased from Sigma-Aldrich (St. Louis, MO Madin-Darby canine kidney (MDCK) cells transfected with the human mdr1 gene (MDCK-MDR1) were a gift from Professor Piet Borst (The Netherlands Cancer Institute, Amsterdam, The Netherlands). The growth media, minimum essential medium (MEM) (for rabbit corneal epithelial cells) and Dulbecco's modified Eagle's medium (for MDCK-MDR1 cells) were obtained from Invitrogen (Carlsbad, CA). Penicillin, streptomycin, sodium bicarbonate, lactalbumin, amphotericin B, polymyxin B sulfate, nonessential amino acids, and HEPES were purchased from Sigma-Aldrich. Fetal bovine serum was procured from JRH Biosciences (Lenexa, KS). The buffer used in transport studies was DPBS containing 129 mM sodium chloride, 2.5 mM potassium chloride, 7.4 mM disodium hydrogen phosphate, 1.3 mM potassium dihydrogen phosphate, 1 mM calcium chloride, 0.7 mM magnesium sulfate, and 5.3 mM glucose at pH 7.4. Culture flasks (75-cm 2 growth area), polyester Transwells (pore size 0.4 m; diameter 6.5 mm), 12-well culture plates (1.1-cm 2 growth area), and polyester membranes (pore size 0.4 m; diameter 1 cm) were obtained from Costar (Cambridge, MA). p-GEM-T-Easy vector and EcoRI were obtained from Promega (Madison, WI) Linear probes (MD-2000, 0.32 ϫ 10 mm, polyacronitrile membrane, 0.22-mm tubing) for aqueous humor sampling were obtained from BAS Bioanalytical Systems (West Lafayette, IN). A microinjection pump (CMA/100), for pumping isotonic buffer was purchased from CMA/Microdialysis (Acton, MA). Ketamine hydrochloride was obtained from Fort Dodge Animal Health (Fort Dodge, IA). Rompun (Xylazine) was obtained from Bayer Animal Health (Shawnee Mission, KS). Nembutal sodium solution was procured from Abbott Laboratories (Abbott Park, IL). Topical wells were custom made by Hansen Ophthalmic Development Corporation (Iowa City, IA) according to specific instructions. The dimensions of the plastic well are depicted in Fig. 1 .
Cell Culture. MDCK-MDR1 cells were maintained at 37°C in a humidified 5% CO 2 , 95% air atmosphere. Cells were seeded at 50,000 cells/cm 2 on polyester Transwell filter inserts (12-well). Experiments were conducted on these cells between 6 and 8 days of culture. Expression of P-gp efflux pump in these transfected cells was examined with Western blotting, and the cells were split twice a week (subculture ratio 1:5). Because the test compound (erythromycin) was 14 C labeled, it was possible to analyze the transport of the test (Dey et al., 2003) . Corneas from New Zealand White rabbits were excised, washed thoroughly with DPBS, blotted dry, and transferred to sterile culture dishes containing 0.5 ml trypsin (0.25%) or 1.2 U/ml protease (Dispase II; Roche Diagnostics, Indianapolis, IN). Corneas were placed upside down (with the concave surface touching the protease solution) and incubated at 37°C for 30 min. The epithelial cells were stripped off with gentle scraping from peripheral areas (1-1.5 mm from the limbus) to the center. Care was taken to peel only the epithelial layer and not the underlying stromal layer because that would contaminate the epithelial cells with keratinocytes. Cells were washed with MEM and placed in culture dishes. After 12 h (when most of the cells have attached to the bottom), MEM medium was removed and fresh MEM medium supplemented with insulin (5 g/ml), transferrin (5 g/ml), sodium selenite (5 ng/ml), amphotericin B (0.25 g/ml), polymyxin B sulfate (0.5 g/ml), penicillin (100 U/ml), streptomycin (100 g/ml), human recombinant epidermal growth factor (10 ng/ml), and bovine pituitary extract (50 g/ml) were added. The media were changed twice a week, and the cells were subcultured every 7 to 10 days (subculture ratio 1:5). Cells reached senescence by passages 7 to 10, so passages 2 to 6 were used for all further experiments.
Transport Experiments. Bidirectional transport of [ 14 C]erythromycin across MDCK-MDR1 was carried out as described previously (Gao et al., 2000) , with some modifications. The purpose of the transport experiment was to determine that erythromycin was a good substrate for P-gp with a good efflux potential which could be used to test the functionality of P-gp in rabbit corneas. 3 H]diazepam) at a concentration of 0.05 Ci/ml was added to the donor side (0.5 ml for the AP chamber and 1.5 ml for the BL chamber), and fresh DPBS was placed in the receiver side. To inhibit the efflux activity of P-gp, cell monolayers were incubated with DPBS containing CsA (10 M) for an additional 20 min. The test compound was added along with CsA (10 M) and fresh DPBS containing the inhibitor was placed in the receiver side. Sink conditions were maintained throughout the experiment. At specified time points, 100 l-aliquots were removed from the receiver chamber and replaced with an equal volume of DPBS. Samples were transferred to scintillation vials containing 5 ml of scintillation cocktail, and its radioactivity was measured. [ 3 H]Mannitol, a paracellular marker, was used simultaneously to assess the integrity of the cell layer for the duration of the experiment. The net efflux of a test compounds was assessed by calculating the ratio of apparent permeability (P app ) in the BL-to-AP direction versus P app in the AP-to-BL direction (P app B3 A/P app A3 B ). A ratio greater than 1.0 indicates net efflux.
Estimation of Cell Cytotoxicity Using Cell Proliferation Assay. Cell proliferation assay was carried out to examine the cytotoxicity of erythromycin and the inhibitors. For this assay CellTiter 96 AQ ueous nonradioactive cell proliferation assay kit (Promega, Madison, WI) was used. This assay is a colorimetric method for determining the number of viable cells in proliferation. The method comprises of a novel tetrazolium compound, 3-(4,5-dimethlythiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) and an electron coupling reagent, phenazine methosulfate (PMS). MTS is bioreduced by cells into a formazan that is soluble in tissue culture medium. The conversion of MTS into the water-soluble formazan is accomplished by dehydrogenase enzymes found in metabolically active cells. The quantity of formazan produced, as measured by the amount at 490 nm absorbance, is directly proportional to the number of viable cells in culture.
rPCEC were plated at passage 3 in 96-well plates, and the seeding density was optimized at 1.25 ϫ 10 4 cells/well. This density was chosen based on the standard Beer-Lambert plot (data not shown) obtained with different seeding densities of the cells at the time points required. A seeding density of 1.25 ϫ 10 4 cells/well produced measurable optical density values that were in the linear range for all the time points.
Solutions of erythromycin and the various inhibitors (at various inhibitory concentrations) were made in the culture medium, and appropriate volumes were added to make up to a final volume of 100 l of medium in each well. A plate was seeded for each time point. The cells were incubated with the solution in a humidified 5% CO 2 atmosphere. The effect of the compounds on the proliferation of these cells was observed with a change in the drug concentration and the time of exposure. Proliferation of rPCEC in the presence of different concentrations of erythromycin and the inhibitors was compared with the positive control (without drug) at each time point, and these values were all corrected for, with a negative control (without cells). Exactly 24 and 48 h after incubating the cells with the drug solutions, 20 l of the MTS/PMS solution was added to each well. The plate was then incubated for another 4 h at 37°C in a humidified 5% CO 2 atmosphere to allow for the dye to interact with the cells. The absorbency of the solutions was read at 490 nm with an automated 96-well microplate reader. Because the amount of formazan produced is directly proportional to the number of viable cells in culture, percentage of viable cells was calculated in each of the drug treated wells compared with the control.
Animal Model. New Zealand albino male rabbits weighing between 5.0 and 5.5 lb were obtained from Myrtle's Rabbitry (Thompson Station, TN). All studies involving rabbits were conducted according to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The animals were kept under anesthesia throughout an experiment with ketamine HCl (35 mg/kg) and xylazine (3.5 mg/kg) given intramuscularly every hour. Before the implantation of the microdialysis probes, pupils were dilated with two drops of 1% tropicamide. The linear probe was implanted in the anterior chamber using a 25-guage needle. It was inserted across the cornea just above the corneal scleral limbus so that it traverses through the center of the anterior chamber to the opposite end of the cornea as evidenced by microscopic examination. The sample-collecting end of the linear probe was inserted carefully into the bevel edge end of the needle. The needle was slowly retracted leaving the probe with the dialyzing membrane in the middle of the anterior chamber. The outlets of both the probes were fixed to prevent any disturbances during sample collection. The probes were perfused with isotonic phosphate buffer saline (pH 7.4) at a flow rate of 2 l/min using a CMA/100 microinjection pump. After probe implantation, the animals were allowed to stabilize for 2 h before the initiation of any study. This duration has been shown to be sufficient for the restoration of intraocular pressure and replenishment of the aqueous humor originally lost during probe implantation (Macha and Mitra, 2001 ). After the 2 h stabilization, the eyelids of the rabbits were mechanically retracted with Colibri retractors, and the topical well was placed over the eye such that the well was right on top of the cornea. This positioning allows the drug solution to be in direct contact with the cornea and exclude the sclera. The outer flange of the topical well was coated with a surgical adhesive to prevent its movement. Subsequent to placing the well, the animals were allowed to stabilize for another 45 min to maintain proper intraocular pressure. After this time period, 150 l of isotonic phosphate-buffered saline containing the radiolabeled compounds [ 14 C]erythromycin (10 Ci/ml), [
14 C]diazepam (10 Ci/ml), or [moved. The corneal surface was washed clean with a few drops of distilled water. Samples were collected every 20 min throughout the infusion and postinfusion phases over a period of 7 h. At the end of an experiment, euthanasia was performed under deep anesthesia with an intravenous injection of sodium pentobarbital through the marginal ear vein. Samples obtained in the study were analyzed by a scintillation counter (LS 6500; Beckman Instruments Inc., Fullerton, CA).
In Vitro Probe Calibration. Microdialysis probe recovery was determined in an aqueous solution containing a known concentration of the compound maintained at physiological temperature. The probe was continuously perfused at a constant flow rate of 2 l/min, and samples were collected every 20 min. The ratio between the concentration of a substance in solution outside the probe is defined as "recovery", usually expressed as a ratio or percentage (Zetterstrom et al., 1982) . The recovery factor of the probes is an important factor in determining the extracellular concentration of the drug. The recovery of a compound of interest is calculated according to eq. 1.
C out is the concentration in the outflow solution and C i the concentration in the medium. The dialysate concentrations were transformed into the actual anterior concentrations by eq. 2.
C i * is the substance concentration in the aqueous humor, and C out * is the concentration of the compound in dialysate.
The recovery of the linear probe was between 10 and 20% for both erythromycin and the inhibitors studied. There was no significant variation in the recovery of the probes with time over the experimental time period.
Mathematical Data Treatment. A model in which drug is administered at a constant rate to the corneal surface from the reservoir has been developed (Fig. 1) . Drugs are transported passively across the cornea into the aqueous humor from where it may reversibly distribute to the adjacent tissues, namely, the iris and ciliary bodies and the lens. Drug is eliminated primarily from the anterior chamber via the aqueous humor pathway (Fig. 1) . Based on this model, the disposition of drug in the aqueous humor can be written as follows:
where k 0 is the constant-input rate from the precorneal area to the aqueous humor; X aq and X PT are the amounts of drug in the aqueous humor compartment and peripheral compartments, respectively; k 10 represents the overall elimination from the aqueous humor; k aq and k PT are the first order rate constants for the transfer of drug from the aqueous humor to the peripheral tissues and vice versa; y is the number of peripheral tissues returning drug to aqueous humor; and x is the number of tissues receiving drug from the aqueous humor that is greater than or equal to y (x Ն y). Peripheral tissues include lens, iris-ciliary body, etc. It is also possible that elimination from peripheral tissues may or may not occur but will not affect the drug disposition in the aqueous humor. The constant-input rate is related to the drug in the precorneal area (well) by eq. 4:
where k a is the first order rate constant for drug transport across the cornea, C w is the concentration of drug in the well, and V w is the volume of the drug solution in the well. Equation 4 can be substituted into eq. 3 and, along with the relationship C aq ‫؍‬ X aq /V aq , can be written as follows:
Equation 5 can be further simplified as follows:
Because at initial times of the infusion the concentration of drug in the well is much greater than concentration of drug in the aqueous humor (C w Ͼ Ͼ C aq ), the first term on the right side of eq. 6 predominates over the second, third, and fourth terms. Thus, eq. 6 can be rewritten as follows:
where V aq is the physiological volume of aqueous humor (250 l). Subscript I in eq. 7 refers to the initial rate that can be determined from the initial slope of C aq versus t. Equation 7 can be rearranged as follows to allow estimation of the corneal absorption rate (k a ):
If the topical infusion is allowed to continue until steady state is reached, then integration of eq. 3 yields eq. 9:
Thus, the topical infusion method along with eqs. 3 to 8 permits a rational and reliable determination of ocular pharmacokinetics whereby absorption, distribution, and elimination can be characterized without using complex compartmental analysis. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). Corneal epithelial tissue (rabbit) and corneal epithelial cells were collected and snap frozen in liquid nitrogen. Total RNA was extracted from these tissues and cells using standard protocol. Briefly, the cells and tissue were taken and 800 l of Tri-LS was added. The cells and tissue were homogenized and transferred to Eppendorf tubes. RNA was extracted by phenol-CHCl 3 -isopropranolol method. Then it is purified and dissolved in 20 l of RNaseDNase-free water.
The forward and reverse primer designed for rabbit MDR1 was 5Ј-CGG ACC ACC ATT GTG ATA GC-3Ј and 5Ј-GGT CGG GTG GGA TAG TTG AA-3Ј, respectively. RT-PCR was performed based on the method of (Sugawara et al., 2000) with modifications using 1 g of total RNA. RT-PCR was carried out using the GeneAmp RNA PCR kit (Applied Biosystems). The conditions for reverse transcription were as follows: denaturation of the template RNA for 10 min at 70°C and reverse transcription for 60 min at 42°C. The conditions for PCR amplification were as follows: denaturation for 1 min at 94°C; annealing for 1 min at 58°C and extension for 1 min at 72°C; 37 cycles; final extension for 10 min at 72°C. The resultant PCR product (ϳ1106 bp) was electrophoresed at 120 V for 30 min in 1% agarose gel (with ethidium bromide).
Analytical Method and Data Treatment. P app was calculated using the following equation:
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org P app denotes the apparent permeability in centimeters per second, dC/dt is the slope of plot of concentration (millimolar) versus time (minutes), C 0 is the initial donor concentration of the drug, V c is the volume of the receiver chamber, and A is the surface area available for diffusion (in polyester Transwells, the surface area for diffusion is 1.1 cm 2 ). Dose-dependent inhibition data were fitted to a dose-response relationship given by eq. 11:
where IC 50 is the inhibitor concentration where the rate of ocular absorption is doubled, and H is the Hill constant. Data were fitted to eq. 4 using a transformed nonlinear regression curve analysis program (GraphPad Prism version 3.03; GraphPad Software Inc., San Diego, CA).
The rate constants for elimination from aqueous chamber were determined by nonlinear regression analysis of the concentrationtime data (Winnonlin, version 2.1; Pharsight, Mountain View, CA). The best fit model for the aqueous concentration-time data of erythromycin was selected based on the coefficient of variation percentage, Akaike's information criterion, F-test, Run-test, and residual plots.
Statistical Testing. All experiments were conducted at least in triplicate and results are expressed as mean Ϯ standard deviation. Statistical significance testing was done using a two-level factorial analysis of variance (Statgraphics Plus, version 5.1; Manugistics, Inc.). A difference between mean values was considered significant if the p value obtained was Յ0.05. The method used to discriminate among the means is Fisher's least significance difference. 14 C]mannitol flux (ϳ0.5%/h). There was no polarity observed of [ 14 C]mannitol transport, suggesting that mannitol was indeed being transported by paracellular pathway (data not shown). The BL3 AP transport of CsA was significantly higher than AP3 BL transport ( Fig. 2A) . The BL3 AP and AP3 BL permeabilities were found to be 4.79 Ϯ 0.32 ϫ 10 Ϫ5 cm/s and 9.83 Ϯ 0.66 ϫ 10 Ϫ6 cm/s, respectively, yielding a ratio (BL3 AP/AP3 BL) of about 5. In the presence of 10 M CsA (inhibitor), both BL3 AP and AP3 BL permeabilities became similar. The BL3 AP and AP3 BL permeabilities in presence of 500 M verapamil were 2.74 Ϯ 0.29 ϫ 10 Ϫ6 and 3.19 Ϯ 0.42 ϫ 10 Ϫ6 cm/s, respectively (Fig. 2B ). Simultaneous transport of [ 3 H]mannitol was also monitored during the transport of erythromycin. Both BL3 AP and AP3 BL permeabilities remained unaltered, indicating no change in membrane characteristics during transport. The mannitol permeability did not change in the presence of 10 M CsA (Fig. 3) .
Results
Transport of [
Dose-Dependent Inhibition of [ 14 C]Erythromycin Absorption across Rabbit Cornea.
To investigate the nature and potency as an inhibitor, dose-dependent inhibition of [
14 C]erythromycin absorption in presence of testosterone was carried out. Testosterone was chosen because it is a very selective inhibitor with no substrate potential for P-gp-mediated efflux. As seen in Fig. 4A 3 H]mannitol uptake was carried out simultaneously in the presence of erythromycin and the P-gp inhibitors. As shown in Fig. 5 , there was a 3-fold increase in the corneal (Table 2 ). As illustrated in Fig. 5 , similar elimination rates were found for both these compounds. Elimination half-life of mannitol was found to be 93 min, whereas the relatively lipophilic compound diazepam had an elimination half-life of 119 min. In addition, the absorption of mannitol was not altered in the presence of erythromycin and the inhibitors, suggesting that the inhibitors used at the specific concentration do not cause any cell damage or change tight junctional properties of the cornea.
In Vivo Ocular Absorption of Erythromycin in Presence of Inhibitors. Ocular absorption of erythromycin in presence of the inhibitors was carried out to determine the functionality of P-gp. Dose-dependent inhibition of [ 14 C]erythromycin was observed with testosterone. However no significant difference was noted in corneal absorption rate or AUC 0-ϱ when testosterone was used at 100 or 150 M. However, a significant inhibition of P-gp efflux (determined by increased absorption) was observed at 250 M with the highest inhibition found at 500 M. At 500 M testosterone, a 4-fold increase in AUC 0-ϱ , 5-fold increase in maximum aqueous concentration (C aq,max ), and a 9-fold increase in the corneal absorption rate were found as compared with control (erythromycin without any testosterone) ( Table 1 ). Higher concentrations of testosterone were not studied because of the difficulty in formulation due to very low aqueous solubility of testosterone. Higher concentration can be achieved by increasing the ethanol concentration; however, that is reported to cause damage to cell morphology.
Other model P-gp inhibitors, including CsA, verapamil, and quinidine were also studied. CsA (20 M) caused significant increase in AUC 0-ϱ (2-fold), k a (3-fold), and C aq,max (2.5-fold) compared with control ( Fig. 4B; Table 2 ). Quinidine (200 M) also caused inhibition of the P-gp-mediated efflux pump. The first order elimination rates (k 10 ) were calculated for all the inhibitors studied to elucidate whether the inhibitors cause any change in the aqueous elimination pathway.
There was no difference observed in the elimination rates for all the inhibitors compared with erythromycin alone. Elimination rate constant (k 10 ) ranged from 4.1 to 5.7 ϫ 10 Ϫ3 min Ϫ1 ) with elimination half-lives ranging from 122 to 169 min.
Estimation of Cell Cytotoxicity by Cell Proliferation Assay. Cell proliferation assay was carried out to examine the toxicity of erythromycin and the various inhibitors. For this assay CellTiter 96 AQ ueous nonradioactive cell proliferation assay kit was used.
Results indicate that erythromycin did not inhibit cell growth (Fig. 6) . Methotrexate was selected as a positive control because it is known to inhibit cell proliferation and cause RT-PCR and Protein Translation. PCR products were analyzed by gel electrophoresis on 0.8% agarose. The forward and reverse primers designed for rabbit MDR1 were 5Ј-CGG ACC ACC ATT GTG ATA GC-3Ј and 5Ј-GGT CGG GTG GGA TAG TTG AA-3Ј, respectively. The forward and reverse primers were designed from human, rat, and mouse cDNA sequences as discussed in our previous report (Dey et al., 2003) . PCR amplification of specific rabbit MDR1 sequences was carried out. When rPCEC and intact rabbit corneal epithelial RNA were PCR amplified, both gave one single product, which is ϳ1100 bp in length (Fig. 7) . The ϳ1100-bp fragment was subcloned in pGEM-T-Easy vector and grown in competent DH5␣ Escherichia coli cells. The cloned insert was sequenced from both T7 and SP6 promoter regions and the sequence matched. The final protein sequence was obtained at ASPET Journals on July 9, 2017 jpet.aspetjournals.org
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using Protein BLAST and the resultant amino acid sequence matched with any known sequences in GenBank. The sequence match showed Ͼ89% homology with human MDR1 protein (Fig. 8) . This partial protein fraction suggests that rabbit corneal epithelial cells express P-gp at the molecular level with high protein homology to human P-gp.
Discussion
P-gp has been demonstrated to be an important determinant of the pharmacokinetics of lipophilic compounds in various body tissues. However, little is known about the functional expression of P-gp in the eye, especially in the corneal epithelium. Moreover, clinical studies are not feasible because of the invasive nature of surgeries required for such pharmacokinetic studies. Substrates recognized by P-gp include many different classes of drugs, some of which are used topically in the eye for the management of ocular diseases.
A majority of topically applied drugs enter the eye through the cornea. Topical delivery is, by far, the most common route of ocular drug delivery. The process of corneal drug absorption has proven to be extremely inefficient. Poor absorption is largely due to precorneal loss and the resistance exerted by the corneal epithelium to drug penetration. Only about 1 to 10% of the topically applied dose actually is absorbed intraocularly. Other restrictive mechanisms include solution drainage, lacrimation, and a highly selective corneal barrier to exclude exogenous compounds from the internal eye structures. Low ocular bioavailability so far was attributed primarily to the inability of drug molecules to cross the lipoidal corneal membrane and not attributed to any efflux proteins that might efflux molecules out of corneal epithelium into the precorneal fluid.
In this present study, we report for the first time the role of P-gp in restricting ocular drug absorption. P-gp has been shown to be present functionally in corneal epithelial cells in culture; however, in vivo determination of P-gp has not been made previously in ocular tissues. We hypothesize that the corneal epithelium is the rate-limiting barrier for most of the drugs administered as topical solution and the presence of P-gp would definitely modulate drug concentration in the aqueous and would directly be responsible for low ocular bioavailability. Thus, it was imperative to choose a proper P-gp substrate that not only has a higher efflux potential (to test the functionality of the pump) but also has a clinical application. Erythromycin was chosen because it is a broadspectrum antibiotic; a large, lipophilic molecule (mol. wt. 733.9) that can be a selective substrate of P-gp. Also, erythromycin (brand name Ilotycin) is being currently used to treat superficial bacterial infection of the cornea/conjunctiva (Queille-Roussel et al., 2001; Kowalski et al., 2003) . Radiolabeled erythromycin transport was studied both from the AP3 BL and BL3 AP directions in MDCK-MDR1 cells to examine whether erythromycin is a good substrate of P-gp. These cells are known to express MDR1 (P-gp) protein in excess. In the past, MDCK cells have been used extensively as models of the intestinal epithelium, to screen drug candidates for efflux potential (Horio et al., 1990; Hunter et al., 1993a,b; Collett et al., 1996; Doppenschmitt et al., 1999) . Transport of [ 14 C]erythromycin across MDCK-MDR1 cell layers confirms the polarized efflux characteristics of P-gp. In absence of any inhibitor BL3 AP permeability was 4.9-fold higher than AP3 BL permeability. In the presence of 10 M CsA, the permeabilities from both sides became approximately equal. This suggests clearly that P-gp is functional and present in the corneal epithelium. Morphological studies have shown that MDCK-MDR1 do not form well defined tight junctions (data not shown). This is reflected in its low TEER values.
So far, the biggest challenge in ocular pharmacokinetic studies of drugs is the inaccessibility of ocular fluids for serial sampling. Microdialysis has been a valuable sampling technique in evaluating drug disposition and pharmacokinetics. The main feature of this sampling procedure is that it does not induce any changes in the physiological volume of the sampling compartment. Ocular microdialysis is a relatively recent event first reported in the late 1980s (Gunnarson et al., 1987) . The application of this technique in ocular drug kinetics has had a major impact on the study of drug disposition in the eye (Sato et al., 1996; Rittenhouse et al., 1999) . It has been used in both the aqueous and vitreous chambers in several laboratories (Hughes et al., 1996; Waga and Ehinger, 1997) . In our laboratory, we have successfully used this technique to study the disposition of drugs in the aqueous and vitreous chambers simultaneously (Macha and Mitra, 2001 ).
Along with aqueous humor microdialysis, we proposed to use a modified ocular model to study the pharmacokinetics of erythromycin that was used earlier to study topical carbonic anhydrase inhibitors (Eller et al., 1985) . Previous ocular pharmacokinetic models have been used with very limited success (Makoid and Robinson, 1979) . These models predict aqueous humor levels reasonably well; however, they fail to measure the transcorneal absorption rate accurately. This is due to the presence of precorneal kinetic events that complicate a compartmental modeling approach. The topical model uses constant concentration of the drug on the cornea by a "topical single-dose infusion" method. This eliminated the effect of tear dynamics and other precorneal losses and simpler equations can be applied independent of modeling. A principal advantage of this topical infusion method is that it obviates the need for compartmental modeling and does not require knowledge of the precorneal factors in estimating k a . The overall goal of this model is to 1) predict corneal absorption rate constants without complications from parallel loss due to non absorptive processes (tear turnover and scleral/ conjunctival absorption) and 2) compare absorption kinetics of erythromycin with and without inhibitors to elucidate the functional nature of P-gp in the cornea. Ocular disposition of mannitol and diazepam was also studied to compare the paracellular and transcellular permeability changes, respec- Fig. 8 . Partial amino acid sequence of rabbit P-gp as obtained from Protein BLAST. The protein sequence was aligned with human P-gp sequence to determine the percentage of homology with human P-gp. The rabbit sequence that does not have an amino acid match with human P-gp is shown in parentheses. From the obtained alignment, rabbit P-gp was found to have 89% protein homology with human P-gp.
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at ASPET Journals on July 9, 2017 jpet.aspetjournals.org tively. The corneal absorption rate for diazepam was found to be 3-fold higher than mannitol. This is because diazepam is relatively more lipophilic than mannitol because the corneal epithelium is more permeable to lipophilic compounds than hydrophilic compounds (Hughes et al., 1993) .
Pharmacokinetic parameters from erythromycin absorption were compared with its inhibitors. Erythromycin was found to have a very low absorption constant. This suggests that erythromycin is actively being effluxed out, and its permeability is much lower than the transcellular component. However with increasing concentration of the inhibitor (testosterone), the corneal absorption is significantly improved. At 500 M testosterone, k a is 9-fold higher than without inhibitor. All other known inhibitors of P-gp also increased the corneal absorption rate with significant increases in the aqueous humor-time AUC 0-ϱ and the maximum aqueous concentration. These results clearly suggest that as P-gp is progressively inhibited, more drug molecules enter the aqueous compartment with increasing rates of absorption and produce higher concentrations in the aqueous. This observation has high clinical significance in the management of ocular diseases. So far, poor ocular bioavailability of topically applied drugs was attributed to precorneal losses and no attempt has been made to increase bioavailability. With this new finding, we could incorporate inhibitors in the ophthalmic formulation that would inhibit P-gp and produce higher concentration inside the eye. In this study we have also tested the inhibitors (same concentration as in vivo studies) for their cytotoxic potential if used along with drugs. None of the inhibitors were found to be cytotoxic (as evident by its inability to stop cell proliferation) and hence can be used along with ophthalmic drugs.
Aqueous humor is presumed to be the primary route of elimination of drug from the eye. In the rabbit eye, the turnover rate of aqueous humor equals a bulk flow rate of 1.5% of the volume of the anterior chamber per minute (t 1/2 ϭ 46 min) (Maurice, 1987) . Half-lives of erythromycin and its inhibitors ranged from 122 to 169 min, which is much longer than the aqueous humor turnover rate, suggesting that tissue binding may have an influence on elimination of drug from the eye. Systemic uptake thorough the highly vascular anterior uvea has been proposed for compounds having very short half-lives. This route of elimination occurs for fluorescein at a rate equal to 10% of the aqueous humor turnover (Jones and Maurice, 1966) . Therefore, this route may not be the predominant route of elimination for the compounds used in this study.
In conclusion, this report provides functional evidence of the existence of P-gp in rabbit cornea. Molecular studies and protein sequence deduction have proven that rabbit MDR1 and human MDR1 share a high sequence homology (89%), which is very much expected because the sequence of genes are conserved within the mammalian system. In the future, cloning and expression of rabbit MDR1 will help us gain valuable insights into the characteristics of this efflux pump. Drug delivery strategies to the cornea and to the inner chambers of the eye will certainly change with this new finding and new ways to bypass P-gp to increase ocular bioavailability will be implemented.
